Literature DB >> 16020502

Challenges in detecting the abuse of growth hormone in sport.

Cathy M McHugh1, Roderick T Park, Peter H Sönksen, Richard I G Holt.   

Abstract

BACKGROUND: Growth hormone (GH) is reputed to be in widespread use in the sporting arena as a performance-enhancing agent and is on the list of banned substances published by the World Anti-Doping Agency. The detection of GH abuse poses many challenges. Unlike many substances of abuse, such as synthetic anabolic steroids, GH is a naturally occurring substance; therefore, demonstration of exogenous administration must rely on detecting concentrations in excess of an established reference interval. The purpose of this review is to discuss the methodologies being developed to detect GH abuse.
METHODS: We undertook a comprehensive search using multiple electronic databases and hand searches of reference lists of articles. The data for this review reflect our academic interests and experience through work on the GH-2000 and GH-2004 projects.
RESULTS: Two approaches have been taken to detect GH abuse. The first is based on assessment of the effect of exogenous GH on pituitary GH isoforms, and the second is based on measurement of markers of GH action. The advantages of each approach and the difficulties encountered with each technique, as well as future concepts in detection, are discussed.
CONCLUSION: Although there are substantial challenges for the detection of GH, methodologies now exist to detect GH abuse with reasonable sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020502     DOI: 10.1373/clinchem.2005.047845

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes.

Authors:  A Sartorio; M Jubeau; F Agosti; N Marazzi; A Rigamonti; E E Müller; N A Maffiuletti
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Strong diabetes.

Authors:  James Young; Aresh Anwar
Journal:  Br J Sports Med       Date:  2007-02-26       Impact factor: 13.800

3.  Exploiting Nanobodies in the Detection and Quantification of Human Growth Hormone via Phage-Sandwich Enzyme-Linked Immunosorbent Assay.

Authors:  Hossam Murad; Jana Mir Assaad; Rasha Al-Shemali; Abdul Qader Abbady
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-30       Impact factor: 5.555

4.  Strong diabetes.

Authors:  James Young; Aresh Anwar
Journal:  BMJ Case Rep       Date:  2009-02-02

5.  Supra-physiological rhGH administration induces gender-related differences in the hypothalamus-pituitary-thyroid (HPT) axis in healthy individuals.

Authors:  P Sgrò; M Sansone; A Parisi; A Sartorio; A Sansone; F Romanelli; A Lenzi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2016-05-26       Impact factor: 4.256

6.  Discrimination of recombinant from natural human growth hormone using DNA aptamers.

Authors:  John G Bruno; Maria P Carrillo; Taylor Phillips; Allison Edge
Journal:  J Biomol Tech       Date:  2011-04

7.  N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.

Authors:  Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 8.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

9.  Salivary free insulin-like growth factor-i levels: effects of an acute physical exercise in athletes.

Authors:  G Antonelli; R Gatti; M Prearo; E F De Palo
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

Review 10.  Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.

Authors:  Bertrand Fougère; Bruno Vellas; Gabor Abellan van Kan; Matteo Cesari
Journal:  Transl Neurosci       Date:  2015-03-17       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.